|
|
||||||||
1 Department of Environmental Health Sciences and 3 Department of Physiology and Biophysics and Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294; and 2 Department of Biochemistry, Kansas State University, Manhattan, Kansas 66506
Cystic fibrosis (CF), an inherited
disease characterized by defective epithelial Cl
transport, damages lungs via chronic inflammation and oxidative stress.
Glutathione, a major antioxidant in the epithelial lung lining fluid,
is decreased in the apical fluid of CF airway epithelia due to reduced
glutathione efflux (Gao L, Kim KJ, Yankaskas JR, and Forman HJ.
Am J Physiol Lung Cell Mol Physiol 277: L113-L118, 1999). The present study examined the question of whether
restoration of chloride transport would also restore glutathione
secretion. We found that a Cl
channel-forming peptide
(N-K4-M2GlyR) and a K+ channel activator
(chlorzoxazone) increased Cl
secretion, measured as
bumetanide-sensitive short-circuit current, and glutathione efflux,
measured by high-performance liquid chromatography, in a human CF
airway epithelial cell line (CFT1). Addition of the peptide alone
increased glutathione secretion (181 ± 8% of the control value),
whereas chlorzoxazone alone did not significantly affect glutathione
efflux; however, chlorzoxazone potentiated the effect of the peptide on
glutathione release (359 ± 16% of the control value). These
studies demonstrate that glutathione efflux is associated with apical
chloride secretion, not with the CF transmembrane conductance regulator
per se, and the defect of glutathione efflux in CF can be overcome pharmacologically.
chlorzoxazone; channel-forming peptide; glutathione transport; antioxidant
This article has been cited by other articles:
![]() |
E. F. McKone, J. Shao, D. D. Frangolias, C. L. Keener, C. A. Shephard, F. M. Farin, M. R. Tonelli, P. D. Pare, A. J. Sandford, M. L. Aitken, et al. Variants in the Glutamate-Cysteine-Ligase Gene Are Associated with Cystic Fibrosis Lung Disease Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 415 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dauletbaev, J. Rickmann, K. Viel, H. Diegel, C. von Mallinckrodt, J. Stein, T. O. F. Wagner, and J. Bargon Antioxidant properties of cystic fibrosis sputum Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L903 - L909. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Venglarik, J. Giron-Calle, A. F. Wigley, E. Malle, N. Watanabe, and H. J. Forman Hypochlorous acid alters bronchial epithelial cell membrane properties and prevention by extracellular glutathione J Appl Physiol, December 1, 2003; 95(6): 2444 - 2452. [Abstract] [Full Text] |
||||
![]() |
L. Gao, J. R. Yankaskas, C. M. Fuller, E. J. Sorscher, S. Matalon, H. J. Forman, and C. J. Venglarik Chlorzoxazone or 1-EBIO increases Na+ absorption across cystic fibrosis airway epithelial cells Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1123 - L1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Pitt CFTR trafficking and signaling in respiratory epithelium Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L13 - L15. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |